Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Simponi, Cimzia REMS A Portent For Rest Of TNF Class

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The Risk Evaluation and Mitigation Strategies for Centocor's Simponi and UCB's Cimzia offer a guide to how sponsors of other tumor necrosis factor inhibitors can be expected to educate physicians about the risk of invasive fungal infections, including histoplasmosis, associated with the class of medications.

You may also be interested in...

TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education

FDA is using its new drug safety authority to require label changes within 30 days for all four products in the tumor necrosis factor inhibitor class

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts